Get the (CYBN) Report Here
Trade with Jim Cramer 14 Days FREE
It may have a tough pill to swallow right now, but I'm still optimistic about psilocybin in general, and especially Cybin.
New technology could take out some of the pain -- and subjectivity -- for those looking to invest in this emerging line of treatments.
AdvisorShares Psychedelics ETF, which is adding Mindset Pharma and lists Cybin as a top holding, looks like a good trip.
To help readers navigate this mushrooming opportunity, I've put together a list of the top corporate leaders in the field.
If your time frame is one to five years, then this is how you need to look at your holdings amid today's action.
This stock will be a winner, but the short-term technical picture may require scaling in patiently.
Follow Real Money's Wall Street Pros to receive real-time investing alerts
Already a Subscriber? Login